

CLAIMS

1. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof comprises
a light chain variable region comprising a CDR1 selected from SEQ ID No.: 1, a CDR2 selected from SEQ ID No.: 2, and a CDR3 selected from SEQ ID No.: 3;
and
a heavy chain variable region comprising a CDR1 selected from SEQ ID No.: 4, a CDR2 selected from SEQ ID No.: 5, and a CDR3 selected from SEQ ID No.: 6.
2. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof comprises
a light chain variable region comprising SEQ ID No.: 9, and
a heavy chain variable region comprising SEQ ID No.: 12 or 13.
3. An isolated Tau-binding antibody or binding fragment thereof of claim 2, wherein said Tau-binding antibody or binding fragment thereof comprises
a light chain comprising SEQ ID No.: 14, and
a heavy chain comprising SEQ ID No.: 17 or 18.
4. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof competes for binding to tau with a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, or 3.
5. An isolated Tau-binding antibody or binding fragment thereof, wherein said Tau-binding antibody or binding fragment thereof binds to the same epitope of Tau as a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, or 3.
6. A Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, or 5, wherein said Tau-binding antibody or binding fragment thereof is a monoclonal humanized antibody.

7. A Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, or 6, wherein said Tau-binding antibody or binding fragment thereof binds to an epitope comprising the amino acid residues of S238, A239, S241, T245, A246, of SEQ ID No.: 35.
8. A Tau-binding antibody or binding fragment thereof of any of embodiments 1, 2, 3, 4, 5, 6, or 7, wherein said Tau-binding antibody or binding fragment thereof binds to an epitope comprising amino acid residues S238, A239, S241, T245, A246 and one or more residues selected from S235, S237, K240, R242, L243, Q244, V248, and M250 of SEQ ID No.: 35.
9. A Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, or 8, wherein said Tau-binding antibody or binding fragment thereof binds to both soluble human and paired helical filaments (PHF) of human tau.
10. An isolated nucleic acid molecule encoding the light and/or heavy chain of a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9.
11. A cloning or expression vector comprising one or more nucleic acid sequences of claim 10.
12. A host cell comprising one or more nucleic acid sequences of claim 10 or one or more cloning or expression vectors of claim 11.
13. A method of producing a Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9, comprising at least the steps of
 - a) culturing a host cell of claim 12, and
 - b) isolating said Tau-binding antibody or binding fragment thereof.
14. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 for use as a therapeutically active agent.

15. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 for use in treating a tauopathy.
16. An isolated Tau-binding antibody or binding fragment thereof for use of claim 15, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.
17. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 for use as a diagnostic agent.
18. An isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 for use in diagnosing a tauopathy.
19. An isolated Tau-binding antibody or binding fragment thereof for use of claim 18, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.
20. Use of an isolated Tau-binding antibody or binding fragment thereof of any of claims 1, 2, 3, 4, 5, 6, 7, 8, or 9 in the manufacture of a medicament for the treatment of tauopathy.
21. The use according to claim 20, wherein said tauopathy is Alzheimer's disease or progressive supranuclear palsy.